

*王宏銘醫師

所有發表期刊論文

1. Chan SC, Chang JT, **Wang HM**, Lin CY, Ng SH, Fan KH, et al. Prediction for distant failure in patients with stage M0 nasopharyngeal carcinoma: the role of standardized uptake value. *Oral Oncol* 2009;45(1):52-8.
2. Chen JS, **Wang HM**, Wu SC, Liu TW, Hung YN, Tang ST. A population-based study on the prevalence and determinants of cardiopulmonary resuscitation in the last month of life for Taiwanese cancer decedents, 2001-2006. *Resuscitation* 2009;80(12):1388-93.
3. Hsu HC, Chang HK, Lin YC, Hseu S, Chen JS, Yang TS, **Wang HM**, Shen WC. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. *Chang Gung Med J* 2009;32(1):33-41.
4. Huang KH, Huang SF, Chen IH, Liao CT, **Wang HM**, Hsieh LL. Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. *Clin Cancer Res* 2009;15(12):4174-80.
5. Huang SF, Chen IH, Liao CT, **Wang HM**, Liou SH, Hsieh LL. Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. *Oral Oncol* 2009;45(1):16-22.
6. Huang SF, Chuang WY, Chen IH, Liao CT, **Wang HM**, Hsieh LL. EGFR protein overexpression and mutation in areca quid-associated oral cavity squamous cell carcinoma in Taiwan. *Head Neck* 2009;31(8):1068-77.
7. Kang CJ, Chen YJ, Liao CT, **Wang HM**, Chang JT, Lin CY, et al. Transcriptome profiling and network pathway analysis of genes associated with invasive phenotype in oral cancer. *Cancer Lett* 2009;284(2):131-40.
8. Liao CT, Chang JT, **Wang HM**, Ng SH, Hsueh C, Lee LY, et al. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. *Int J Radiat Oncol Biol Phys* 2009;73(3):764-71.
9. Liao CT, Chang JT, **Wang HM**, Ng SH, Hsueh C, Lee LY, et al. Preoperative [18F]fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes. *Int J Radiat Oncol Biol Phys* 2009;74(4):1054-61.
10. Liao CT, Chang JT, **Wang HM(co-1st)**, Ng SH, Huang SF, Chen IH, et al.

Preoperative [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. *Eur J Nucl Med Mol Imaging* 2009;36(11):1783-93.

11. Liao CT, Huang SF, Chen IH, Chang JT, **Wang HM**, Ng SH, et al. Risk stratification of patients with oral cavity squamous cell carcinoma and contralateral neck recurrence following radical surgery. *Ann Surg Oncol* 2009;16(1):159-70.
12. Liu TW, Chen JS, **Wang HM**, Wu SC, Hung YN, Tang ST. Quality of end-of-life care between medical oncologists and other physician specialists for Taiwanese cancer decedents, 2001-2006. *Oncologist* 2009;14(12):1232-41.
13. Ng SH, Chan SC, Yen TC, Chang JT, Liao CT, Ko SF, **Wang HM**, Wai YY, Wang JJ, Chen MC. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT. *Eur Radiol* 2009 Dec;19(12):2965-76.
14. Yeh SL, **Wang HM**, Chen PY, Wu TC. Interactions of beta-carotene and flavonoids on the secretion of pro-inflammatory mediators in an in vitro system. *Chem Biol Interact* 2009;179(2-3):386-93.
15. Chan SC, Lin CY, Ng SH, Chang JT, **Wang HM**, Liao CT, et al. 18F-FDG PET for retropharyngeal lymph node metastasis in oropharyngeal and hypopharyngeal cancers: impact on diagnosis and prediction analysis. *Nucl Med Commun* 2010;31(3):260-5.
16. Chang JT, Lin CY, Lin JC, Lee MS, Chen YJ, **Wang HM (corresponding)**. Transdermal fentanyl for pain caused by radiotherapy in head and neck cancer patients treated in an outpatient setting: a multicenter trial in Taiwan. *Jpn J Clin Oncol* 2010;40(4):307-12.
17. Chang MF, **Wang HM**, Kang CJ, Huang SF, Lin CY, Fang KH, et al. Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan. *Radiat Oncol* 2010;5:91.
18. Chen YJ, Liao CT, Chen PJ, Lee LY, Li YC, Chen IH, et al. Downregulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract. *Head Neck* 2010.
19. Fan KH, **Wang HM**, Kang CJ, Lee LY, Huang SF, Lin CY, et al. Treatment results of postoperative radiotherapy on squamous cell carcinoma of the oral cavity: coexistence of multiple minor risk factors results in higher recurrence rates. *Int J Radiat Oncol Biol Phys* 2010;77(4):1024-9.
20. Hou MM, Hsieh JJ, Chang NJ, Huang HY, **Wang HM**, Chuang CK, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal

cell carcinoma. *Clin Drug Investig* 2010;30(11):799-804.

21. Liao CT, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, **Wang HM**, Ng SH, Hsueh C, Lee LY, Lin CH, Yen TC. Tongue and buccal mucosa carcinoma: is there a difference in outcome? *Ann Surg Oncol* 2010;17(11):2984-91.
22. Liao CT, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, **Wang HM**, Ng SH, Hsueh C, Lee LY, Tsao CK, Yen TC. Outcome analysis of patients with pN2 oral cavity cancer. *Ann Surg Oncol* 2010;17(4):1118-26.
23. Liao CT, Lee LY, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, **Wang HM**, Ng SH, Yen TC. Outcome Analysis of Patients with Oral Cavity Cancer and Extracapsular Spread in Neck Lymph Nodes. *Int J Radiat Oncol Biol Phys* 2010.
24. Liao CT, **Wang HM**(co 1st), Chang JT, Lin CY, Ng SH, Huang SF, et al. Influence of pathological nodal status and maximal standardized uptake value of the primary tumor and regional lymph nodes on treatment plans in patients with advanced oral cavity squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 2010;77(2):421-9.
25. Lin CY, Chen WH, Liao CT, Chen IH, Chiu CC, **Wang HM**, et al. Positive association of glucose-regulated protein 78 during oral cancer progression and the prognostic value in oral precancerous lesions. *Head Neck* 2010;32(8):1028-39.
26. Lin CY, **Wang HM**, Kang CJ, Lee LY, Huang SF, Fan KH, et al. Primary tumor site as a predictor of treatment outcome for definitive radiotherapy of advanced-stage oral cavity cancers. *Int J Radiat Oncol Biol Phys* 2010;78(4):1011-9.
27. Lin TY, Chang JT, **Wang HM**, Chan SH, Chiu CC, Lin CY, et al. Proteomics of the radioresistant phenotype in head-and-neck cancer: Gp96 as a novel prediction marker and sensitizing target for radiotherapy. *Int J Radiat Oncol Biol Phys* 2010;78(1):246-56.
28. Ng SH, Chan SC, Yen TC, Liao CT, Chang JT, Ko SF, **Wang HM**, Lin CY, Chang KP, Lin YC. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT. *Eur Radiol* 2010;20(9):2229-40.
29. Tang ST, Huang EW, Liu TW, **Wang HM**, Chen JS. A population-based study on the determinants of hospice utilization in the last year of life for Taiwanese cancer decedents, 2001-2006. *Psychooncology* 2010;19(11):1213-20.
30. Tang ST, Huang EW, Liu TW, **Wang HM**, Rau KM, Chen JS. Aggressive End-of-Life Care Significantly Influenced Propensity for Hospice Enrollment Within the Last Three Days of Life for Taiwanese Cancer Decedents. *J Pain*

Symptom Manage 2010.

31. Wu SC, Chen JS, **Wang HM**, Hung YN, Liu TW, Tang ST. Determinants of ICU care in the last month of life for Taiwanese cancer decedents, 2001 to 2006. *Chest* 2010;138(5):1071-7.
32. Wu TH, Huang JS, **Wang HM**, Chang JW, Song GG, Wang CH, et al. Long-term survival after surgery for stage III-IV maxillary sinus carcinoma. *B-ENT* 2010;6(1):35-41.
33. Wu YH, **Wang HM**, Chen HH, Lin CY, Chen EY, Fan KH, et al. Hypothyroidism after radiotherapy for nasopharyngeal cancer patients. *Int J Radiat Oncol Biol Phys* 2010;76(4):1133-9.
34. Yang MH, Chang PM, Tzeng CH, Chang SY, Chu PY, Tai SK, Tsai TL, Wang YF, Huang JL, **Wang HM**, Chen PM. Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study. *Cancer Chemother Pharmacol* 2010;65(2):259-65.
35. Yeh KY, Chang JW, Li YY, Wang CH, **Wang HM**. Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. *Head Neck* 2010.
36. Abd El-Hafez YG, Chen CC, Ng SH, Lin CY, **Wang HM**, Chan SC, et al. Comparison of PET/CT and MRI for the detection of bone marrow invasion in patients with squamous cell carcinoma of the oral cavity. *Oral Oncol* 2011;47(4):288-95.
37. Chan SC, Chang JT, Lin CY, Ng SH, **Wang HM**, Liao CT, et al. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification. *Nucl Med Commun* 2011;32(11):989-96.
38. Chan SC, **Wang HM(co-1st)**, Yen TC, Lin CY, Chin SC, Liao CT, et al. (1)(8)F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study. *Eur J Nucl Med Mol Imaging* 2011;38(9):1607-19.
39. Chen YJ, Liao CT, Chen PJ, Lee LY, Li YC, Chen IH, **Wang HM**, Chang JT, Chen LJ, Yen TC, Tang CY, Cheng AJ. Downregulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract. *Head Neck* 2011;33(2):257-66.
40. Chien HT, Liao CT, Huang SF, Chen IH, Liu TY, Jou YS, **Wang HM**, Hsieh LL. Clinical significance of genome-wide minimally deleted regions in oral

- squamous cell carcinomas. *Genes Chromosomes Cancer* 2011;50(5):358-69.
41. Chiu CC, Lin CY, Lee LY, Chen YJ, Lu YC, **Wang HM**, et al. Molecular chaperones as a common set of proteins that regulate the invasion phenotype of head and neck cancer. *Clin Cancer Res* 2011;17(14):4629-41.
 42. Gregoire V. Hamoir M. Chen C. Kane M. Kawecki A. Julka PK. **Wang HM**. Prasad S. D'Cruz AK. Radosevic-Jelic L. Kumar RR. Korzeniowski S. Fijuth J. Machiels JP. Sellers MV. Tchakov I. Raben D. Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. *Radiother Oncol* 2011;100(1):62-9.
 43. Han BH, Xiu QY, **Wang HM**, Shen J, Gu AQ, Luo Y, et al. [A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxel-carboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC)]. *Zhonghua Zhong Liu Za Zhi* 2011;33(11):854-9.
 44. Hsieh CH, Chang JW, Hsieh JJ, Hsu T, Huang SF, Liao CT, **Wang HM (corresponding)**. Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. *Head Neck* 2011;33(12):1758-64.
 45. Kang CJ, Liao CT, Hsueh C, Lee LY, Lin CY, Fan KH, **Wang HM**, Huang SF, Chen IH, Ng SH, Tsao CK, Huang YC, Yen TC. Outcome analysis of patients with well-differentiated oral cavity squamous cell carcinoma. *Oral Oncol* 2011;47(11):1085-91.
 46. Kang CJ, Lin CY, **Wang HM**, Fan KH, Ng SH, Lee LY, et al. The number of pathologically positive lymph nodes and pathological tumor depth predicts prognosis in patients with poorly differentiated squamous cell carcinoma of the oral cavity. *Int J Radiat Oncol Biol Phys* 2011;81(4):e223-30.
 47. Liao CT, Lee LY, Huang SF, Chen IH, Kang CJ, Lin CY, Fan KH, **Wang HM**, Ng SH, Yen TC. Outcome analysis of patients with oral cavity cancer and extracapsular spread in neck lymph nodes. *Int J Radiat Oncol Biol Phys* 2011;81(4):930-7.
 48. Liao CT, Lin CY, Fan KH, Huang SF, Chen IH, Kang CJ, **Wang HM**, Ng SH, Hsueh C, Lee LY, Lin CH, Yen TC. Identification of a high-risk subgroup of patients with resected pT3 oral cavity cancer in need of postoperative adjuvant therapy. *Ann Surg Oncol* 2011;18(9):2569-78.
 49. Liao CT, **Wang HM**, Huang SF, Chen IH, Kang CJ, Lin CY, et al. PET and PET/CT of the neck lymph nodes improves risk prediction in patients with squamous cell carcinoma of the oral cavity. *J Nucl Med* 2011;52(2):180-7.

50. Lin CY, Lin TY, **Wang HM**, Huang SF, Fan KH, Liao CT, et al. GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy. *Radiat Oncol* 2011;6:136.
51. Lin WH. Chen IH. Wei FC. Huang JJ. Kang CJ. Hsieh LL. **Wang HM**. Huang SF. Clinical significance of preoperative squamous cell carcinoma antigen in oral-cavity squamous cell carcinoma. *Laryngoscope* 2011;121(5):971-7.
52. Liu CH, Tang WR, **Wang HM**, Lee KC. Cancer patients' experience of combined treatment with conventional and traditional Chinese medicine: a biopsychosocial phenomenon. *Cancer Nurs* 2011;34(6):495-502.
53. Ng SH. Chan SC. Yen TC. Liao CT. Lin CY. Tung-Chieh Chang J. Ko SF. **Wang HM**. Chang KP. Fan KH. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. *Eur J Nucl Med Mol Imaging* 2011;38(6):996-1008.
54. Su PJ, Chen JS, Liaw CC, Chang HK, **Wang HM**, Yang TS, et al. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma. *Chang Gung Med J* 2011;34(5):478-86.
55. **Wang HM**, Koong SL, Hsiao SC, Chen JS, Liu TW, Tang ST. Impact of availability of an inpatient hospice unit on the parent hospital's quality of palliative care for Taiwanese cancer decedents, 2001-2006. *J Pain Symptom Manage* 2011;42(3):400-9.
56. Yeh KY, Chang JW, Li YY, Wang CH, **Wang HM**. Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. *Head Neck* 2011;33(5):734-42.
57. Chan SC, **Wang HM(co-1st)**, Ng SH, Hsu CL, Lin YJ, Lin CY, et al. Utility of 18F-fluoride PET/CT and 18F-FDG PET/CT in the detection of bony metastases in heightened-risk head and neck cancer patients. *J Nucl Med* 2012;53(11):1730-5.
58. Chang KP. Tsang NM. Liao CT. Hsu CL. Chung MJ. Lo CW. Chan SC. Ng SH. **Wang HM**. Yen TC. Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma. *J Nucl Med* 2012;53(1):21-8.
59. Chen JS. Chen YY. Huang JS. Yeh KY. Chen PT. Shen WC. Hsu HC. Lin YC. **Wang HM**. A multiple-center phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. *Gastric Cancer* 2012;15(1):49-55.
60. Cheng NM, Chang JT, Huang CG, Tsan DL, Ng SH, **Wang HM**, et al. Prognostic

value of pretreatment (1)(8)F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma. *Eur J Nucl Med Mol Imaging* 2012;39(11):1673-84.

61. Cheng WH, Kao CY, Hung YS, Su PJ, Hsieh CH, Chen JS, **Wang HM**, Chou WC. Validation of a palliative prognostic index to predict life expectancy for terminally ill cancer patients in a hospice consultation setting in Taiwan. *Asian Pac J Cancer Prev* 2012;13(6):2861-6.
62. Feng Y, Xiao YY, Li SD, Lin MX, Zhang Y, **Wang HM**, et al. The treatment of non-small cell lung cancer by interstitial I-125 seeds implantation combined with chemotherapy and Chinese medicine. *Chin J Integr Med* 2012;18(9):663-9.
63. Hou MM, Huang SF, Kuo HP, Yang CT, Tsai YH, Yu CT, Lin HC, Chen CH, Wang CL, Chung FT, Hsieh JJ, Hsu T, Cheng HY, Ou LY, **Wang HM**, Lin YC, Chang NJ, Chang JW. Erlotinib treatment in patients with advanced lung adenocarcinoma with CISH-positive and CISH-negative EGFR gene alterations. *Anticancer Res* 2012;32(3):1107-12.
64. Hsu CL, Chang KP, Lin CY, Chang HK, Wang CH, Lin TL, Liao CT, Tsang NM, Lee LY, Chan SC, Ng SH, Li HP, Chang YS, **Wang HM (corresponding)**. Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma. *Head Neck* 2012;34(8):1064-70.
65. Huang SF, Cheng SD, Chien HT, Liao CT, Chen IH, **Wang HM**, et al. Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. *Oral Oncol* 2012;48(1):67-72.
66. Huang SF, Cheng SD, Chuang WY, Chen IH, Liao CT, **Wang HM**, et al. Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. *World J Surg Oncol* 2012;10:40.
67. Huang SF, Li HF, Liao CT, **Wang HM**, Chen IH, Chang JT, et al. Association of HPV infections with second primary tumors in early-staged oral cavity cancer. *Oral Dis* 2012;18(8):809-15.
68. Huang SF, Wei FC, Liao CT, **Wang HM**, Lin CY, Lo S, et al. Risk stratification in oral cavity squamous cell carcinoma by preoperative CRP and SCC antigen levels. *Ann Surg Oncol* 2012;19(12):3856-64.
69. Huang WK, Liaw CC, Pang ST, Chuang CK, Chiang YJ, Wu CT, Chang YH, **Wang HM**, Lin YC, Hsieh JJ, Ou LY, Tsai SI, Yang CH, Yang CT, Chang WC. Everolimus in metastatic renal cell carcinoma: preliminary experience from Chang Gung Memorial Hospital. *Chang Gung Med J* 2012;35(5):402-7.

70. Lee LA, Huang CG, Liao CT, Lee LY, Hsueh C, Chen TC, Lin CY, Fan KH, **Wang HM**, Huang SF, Chen IH, Kang CJ, Ng SH, Yang SL, Tsao KC, Chang YL, Yen TC. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. *PLoS One* 2012;7(7):e40767.
71. Liao CT, Fan KH, Lin CY, **Wang HM**, Huang SF, Chen IH, et al. Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread. *Eur J Nucl Med Mol Imaging* 2012;39(6):944-55.
72. Liao CT, Hsueh C, Lee LY, Lin CY, Fan KH, **Wang HM**, et al. Neck dissection field and lymph node density predict prognosis in patients with oral cavity cancer and pathological node metastases treated with adjuvant therapy. *Oral Oncol* 2012;48(4):329-36.
73. Liao CT, Lin CY, Fan KH, **Wang HM**, Ng SH, Lee LY, et al. Identification of a high-risk group among patients with oral cavity squamous cell carcinoma and pT1-2N0 disease. *Int J Radiat Oncol Biol Phys* 2012;82(1):284-90.
74. Tsan DL, Lin CY, Kang CJ, Huang SF, Fan KH, Liao CT, Chen IH, Lee LY, **Wang HM (corresponding)**, Chang JT. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. *Radiat Oncol* 2012;7:215.
75. Wang CH, **Wang HM**, Pang YP, Yeh KY. Early nutritional support in non-metastatic stage IV oral cavity cancer patients undergoing adjuvant concurrent chemoradiotherapy: analysis of treatment tolerance and outcome in an area endemic for betel quid chewing. *Support Care Cancer* 2012;20(6):1169-74.
76. Wu CE, Hsu HC, Shen WC, Lin YC, **Wang HM**, Chang JW, et al. Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: a retrospective analysis. *Chang Gung Med J* 2012;35(5):420-7.
77. Chan SC, Hsu CL, Yen TC, Ng SH, Liao CT, **Wang HM**. The role of 18F-FDG PET/CT metabolic tumour volume in predicting survival in patients with metastatic nasopharyngeal carcinoma. *Oral Oncol* 2013;49(1):71-8.
78. Chan SC, Kuo WH, **Wang HM**, Chang JT, Lin CY, Ng SH, et al. Prognostic implications of post-therapy (18)F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. *Ann Nucl Med* 2013;27(8):710-9.

79. Chen HH, **Wang HM**, Fan KH, Lin CY, Yen TC, Liao CT, et al. Pre-treatment levels of C-reactive protein and squamous cell carcinoma antigen for predicting the aggressiveness of pharyngolaryngeal carcinoma. *PLoS One* 2013;8(1):e55327.
80. Cheng NM, Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, **Wang HM**, Lin CY.
81. Liao CT, Yen TC. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. *J Nucl Med* 2013;54(10):1703-9.
82. Chou WC, Hung YS, Kao CY, Su PJ, Hsieh CH, Chen JS, Liao CT, Lin YC, Liaw CC. **Wang HM(corresponding)**. Impact of palliative care consultative service on disease awareness for patients with terminal cancer. *Support Care Cancer* 2013;21(7):1973-81.
83. Fang HY, Huang XY, Chien HT, Tung-Chieh Chang J, Liao CT, Huang JJ, Wei FC. **Wang HM**, Chen IH, Kang CJ, Huang SF. Refining the role of preoperative C-reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinoma. *Laryngoscope* 2013.
84. Hsieh CH, Hsu CL, Wang CH, Liaw CC, Chen JS, Chang HK, Yang TS, Chang JW, Lin YC, Liao CT, Tsang NM, Chang JT, Ng SH, **Wang, HM(corresponding)**. Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma. *Biomed J* 2013;36(5):229-36.
85. Hsu CL, Chan SC, Chang KP, Lin TL, Lin CY, Hsieh CH, Huang SF, Tsang NM, Lee LY, Ng SH, **Wang HM(corresponding)**. Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma. *Oral Oncol* 2013;49(6):620-5.
86. Hung TM, **Wang HM**, Kang CJ, Huang SF, Liao CT, Chan SC, et al. Pretreatment (18)F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. *Oral Oncol* 2013;49(2):169-74.
87. Hung YS, Wu JH, Chang H, Wang PN, Kao CY, **Wang HM**, et al. Characteristics of patients with hematologic malignancies who received palliative care consultation services in a medical center. *Am J Hosp Palliat Care* 2013;30(8):773-80.
88. Kao CY, **Wang HM**, Tang SC, Huang KG, Jaing TH, Liu CY, et al. Predictive Factors For Do-Not-Resuscitate Designation Among Terminally Ill Cancer Patients Receiving Care From a Palliative Care Consultation Service. *J Pain Symptom Manage* 2013.
89. Lai CH, Huang SF, Liao CT, Chen IH, **Wang HM**, Hsieh LL. Clinical significance

in oral cavity squamous cell carcinoma of pathogenic somatic mitochondrial mutations. PLoS One 2013;8(6):e65578.

90. Lee LA, Huang CG, Tsao KC, Liao CT, Kang CJ, Chang KP, Huang SF, Chen IH, Fang T J, Li HY, Yang SL, Lee LY, Hsueh C, Chen TC, Lin CY, Fan KH, **Wang HM**, Ng SH, Chang Y L, Lai CH, Shih SR, Yen TC. Increasing rates of low-risk human papillomavirus infections in patients with oral cavity squamous cell carcinoma: Association with clinical outcomes. J Clin Virol 2013;57(4):331-7.
91. Liao CT, Lee LY, Hsueh C, Lin CY, Fan KH, **Wang HM**, et al. Comparative outcomes in oral cavity cancer with resected pT4a and pT4b. Oral Oncol 2013;49(3):230-6.
92. Liao CT, Lin CY, Fan KH, Hsueh C, Lee LY, **Wang HM**, et al. Outcome analyses of unusual site neck recurrence in oral cavity cancer. Ann Surg Oncol 2013;20(1):257-66.
93. Ng SH, Lin CY, Chan SC, Yen TC, Liao CT, Chang JT, Ko SF, **Wang HM**, Huang SF, Lin YC, Wang JJ. Dynamic contrast-enhanced MR imaging predicts local control in oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. PLoS One 2013;8(8):e72230.
94. Tseng JR, Ho TY, Lin CY, Lee LY, **Wang HM**, Liao CT, et al. Clinical Outcomes of Patients with Oral Cavity Squamous Cell Carcinoma and Retropharyngeal Lymph Node Metastasis Identified by FDG PET/CT. PLoS One 2013;8(11):e79766.
95. Yeh KY, **Wang HM**, Chang JW, Huang JS, Lai CH, Lan YJ, et al. Omega-3 fatty acid-, micronutrient-, and probiotic-enriched nutrition helps body weight stabilization in head and neck cancer cachexia. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116(1):41-8.
96. Lin HC, Hsu HC, Hsieh CH, **Wang HM**, Huang CY, Wu MH, et al. A negative selection system PowerMag for effective leukocyte depletion and enhanced detection of EpCAM positive and negative circulating tumor cells. Clin Chim Acta 2013;419:77-84.
97. **Wang HM**, Hsu CL, Heish CH, Fan KH, Lin C.Y, Chang JTC, Huang SF, Chen IH, Liao CT, Ng SK. Concurrent Chemoradiotherapy Using Cisplatin, Tegafur and Leucovorin for Advanced Squamous Cell Carcinoma of the Hypopharynx and Oropharynx. Biomed J 2014 (ahead of print).